Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists. 2016

Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago , Chicago, Illinois 60612, United States.

On the basis of the structural similarity of our previous 5-HT2C agonists with the melatonin receptor agonist tasimelteon and the putative biological cross-talk between serotonergic and melatonergic systems, a series of new (2,3-dihydro)benzofuran-based compounds were designed and synthesized. The compounds were evaluated for their selectivity toward 5-HT2A, 5-HT2B, and 5-HT2C receptors in the calcium flux assay with the ultimate goal to generate selective 5-HT2C agonists. Selected compounds were studied for their functional selectivity by comparing their transduction efficiency at the G protein signaling pathway versus β-arrestin recruitment. The most functionally selective compound (+)-7e produced weak β-arrestin recruitment and also demonstrated less receptor desensitization compared to serotonin in both calcium flux and phosphoinositide (PI) hydrolysis assays. We report for the first time that selective 5-HT2C agonists possessing weak β-arrestin recruitment can produce distinct receptor desensitization properties.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D044405 Receptor, Serotonin, 5-HT2C A serotonin receptor subtype found primarily in the CENTRAL NERVOUS SYSTEM and the CHOROID PLEXUS. This receptor subtype is believed to mediate the anorectic action of SEROTONIN, while selective antagonists of the 5-HT2C receptor appear to induce ANXIETY. Several isoforms of this receptor subtype exist, due to adenine deaminase editing of the receptor mRNA. Serotonin 2C Receptor,5-HT(2C) Receptor,5-HT2C Receptor,5-Hydroxytryptamine Type 2C Receptor,5-Hydroxytryptamine Type 2C Receptors,Receptor, 5-Hydroxytryptamine Type 2C,5 HT2C Receptor,5 Hydroxytryptamine Type 2C Receptor,5 Hydroxytryptamine Type 2C Receptors,Receptor, 5 Hydroxytryptamine Type 2C,Receptor, 5-HT2C,Receptor, Serotonin 2C
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug
D058826 Serotonin 5-HT2 Receptor Agonists Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT2 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT2 receptor subtypes. 5-HT2 Agonist,5-HT2 Agonists,5-HT2A Agonist,5-HT2B Agonist,5-HT2C Agonist,Serotonin 5-HT2A Receptor Agonists,Serotonin 5-HT2B Receptor Agonists,Serotonin 5-HT2C Receptor Agonists,5 HT2 Agonist,5 HT2 Agonists,5 HT2A Agonist,5 HT2B Agonist,5 HT2C Agonist,Agonist, 5-HT2,Agonist, 5-HT2A,Agonist, 5-HT2B,Agonist, 5-HT2C,Agonists, 5-HT2,Serotonin 5 HT2 Receptor Agonists,Serotonin 5 HT2A Receptor Agonists,Serotonin 5 HT2B Receptor Agonists,Serotonin 5 HT2C Receptor Agonists

Related Publications

Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
July 2006, Journal of medicinal chemistry,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
August 2016, Bioorganic & medicinal chemistry letters,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
December 2015, ChemMedChem,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
March 2012, ChemMedChem,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
October 2005, Molecular interventions,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
August 1996, Psychopharmacology,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
July 2023, Journal of medicinal chemistry,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
September 2009, Bioorganic & medicinal chemistry letters,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
February 1999, IDrugs : the investigational drugs journal,
Jianjun Cheng, and John D McCorvy, and Patrick M Giguere, and Hu Zhu, and Terry Kenakin, and Bryan L Roth, and Alan P Kozikowski
June 2022, Bioorganic chemistry,
Copied contents to your clipboard!